These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 12680162)
1. Tumour 'budding' and its relationship to p53 and Bcl-2 expression in colorectal cancer. Guzińska-Ustymowicz K; Sulkowska M; Famulski W; Sulkowski S Anticancer Res; 2003; 23(1B):649-53. PubMed ID: 12680162 [TBL] [Abstract][Full Text] [Related]
2. Differential expression of Bcl-2, Bcl-XL and p53 in colorectal cancer. Han HS; Park YM; Hwang TS J Gastroenterol Hepatol; 2006 Jul; 21(7):1108-14. PubMed ID: 16824061 [TBL] [Abstract][Full Text] [Related]
3. The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer. Sjöström-Mattson J; Von Boguslawski K; Bengtsson NO; Mjaaland I; Salmenkivi K; Blomqvist C Acta Oncol; 2009; 48(8):1137-43. PubMed ID: 19863221 [TBL] [Abstract][Full Text] [Related]
4. Correlation between colorectal cancer Bcl-2 expression and tumour clinicopathological variables. Guzińska-Ustymowicz K; Famulski W; Stasiak-Barmuta A; Zalewski B; Sulkowska M Rocz Akad Med Bialymst; 2002; 47():246-53. PubMed ID: 12533967 [TBL] [Abstract][Full Text] [Related]
5. Apoptosis loss and bcl-2 expression: key determinants of lymph node metastases in T1 breast cancer. Sierra A; Castellsagué X; Tórtola S; Escobedo A; Lloveras B; Peinado MA; Moreno A; Fabra A Clin Cancer Res; 1996 Nov; 2(11):1887-94. PubMed ID: 9816145 [TBL] [Abstract][Full Text] [Related]
6. p53 as an indicator of lymph node metastases in invasive early colorectal cancer. Makino M; Yamane N; Taniguchi T; Honboh T; Kurayoshi K; Kaibara N Anticancer Res; 2000; 20(3B):2055-9. PubMed ID: 10928151 [TBL] [Abstract][Full Text] [Related]
7. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors? Zafirellis K; Karameris A; Milingos N; Androulakis G Anticancer Res; 2005; 25(5):3629-36. PubMed ID: 16101192 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices. Ioachim EE; Goussia AC; Machera M; Tsianos EV; Kappas AM; Agnantis NJ Anticancer Res; 1999; 19(3A):2147-55. PubMed ID: 10470163 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance. Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742 [TBL] [Abstract][Full Text] [Related]
10. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up. Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236 [TBL] [Abstract][Full Text] [Related]
11. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer. Guzińska-Ustymowicz K; Pryczynicz A; Kemona A; Czyzewska J Anticancer Res; 2009 Aug; 29(8):3049-52. PubMed ID: 19661314 [TBL] [Abstract][Full Text] [Related]
12. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Ioachim E Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860 [TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135 [TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience. Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036 [TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-beta1 and regulators of apoptosis. Sulkowski S; Wincewicz A; Sulkowska M; Koda M Ann N Y Acad Sci; 2009 Aug; 1171():116-23. PubMed ID: 19723045 [TBL] [Abstract][Full Text] [Related]
16. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739 [TBL] [Abstract][Full Text] [Related]
17. Expression of phosphorylated Ser70 of Bcl-2 correlates with malignancy in human colorectal neoplasms. Kondo E; Miyake T; Shibata M; Kimura T; Iwagaki H; Nakamura S; Tanaka T; Ohara N; Ichimura K; Oka T; Yanai H; Shibasaki F; Yoshino T Clin Cancer Res; 2005 Oct; 11(20):7255-63. PubMed ID: 16243795 [TBL] [Abstract][Full Text] [Related]
18. Activity of cathepsin B and D in colorectal cancer: relationships with tumour budding. Guzińska-Ustymowicz K; Zalewski B; Kasacka I; Piotrowski Z; Skrzydlewska E Anticancer Res; 2004; 24(5A):2847-51. PubMed ID: 15517887 [TBL] [Abstract][Full Text] [Related]
19. Expression of Bcl-xL, Bax, and p53 in primary tumors and lymph node metastases in oral squamous cell carcinoma. Baltaziak M; Duraj E; Koda M; Wincewicz A; Musiatowicz M; Kanczuga-Koda L; Szymanska M; Lesniewicz T; Musiatowicz B Ann N Y Acad Sci; 2006 Dec; 1090():18-25. PubMed ID: 17384243 [TBL] [Abstract][Full Text] [Related]
20. MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Guzińska-Ustymowicz K Anticancer Res; 2006; 26(2B):1589-94. PubMed ID: 16619576 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]